期刊
NEPHRON
卷 136, 期 4, 页码 277-280出版社
KARGER
DOI: 10.1159/000448183
关键词
Hyperfiltration; Diabetes; Intraglomerular pressure; Diabetic nephropathy
资金
- Astra-Zeneca
- Boehringer Ingelheim
- Eli Lilly
- Novo Nordisk
- Janssen
- Merck
Hyperfiltering kidney is a typical feature of diabetes. Improvement observed with regard to glucose control and blood pressure control reduces the high glomerular filtration rate and may contribute to retard the appearance and the progression of diabetic renal disease. Although the mechanism of hyperfiltration is still unclear, there is mounting evidence that the increased reabsorption of glucose and sodium by sodium glucose transporter-2 (SGLT-2) is involved in this altered renal function. There is a possibility that SGLT-2 inhibition may correct hyperfiltration in diabetes, adding a new therapeutic approach to halt renal disease in patients with diabetes. (C) 2016 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据